Researchers developed a computational model to optimize drug selection for chronic myelogenous leukemia (CML), tailoring ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company.

Tempus AI, Inc. TEM recently announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement ...

A study co-led by UCLA scientists has found targeting a protein called endocan and its related signaling pathway could be a ...

In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist ...

Jan. 8, 2025 — Research demonstrates that AI can determine the course and severity of aggressive skin cancers, such as Merkel cell carcinoma (MCC), to enhance clinical decision making by ...

These alternative pathways may bypass or evade inhibition of EGFR signaling, thereby enabling combinations of agents to simultaneously attack multiple molecular targets for cancer growth inhibition.

Jan. 6, 2025 — Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer ... Scientists Develop Scans That Light-Up Aggressive ...

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

You might have a change of heart today and feel like bailing on social plans at the eleventh hour. Chalk it up to a meeting between your ruler, the moon, and impromptu Uranus in your collective ...

Oncolytic adenoviruses were designed to reach potent intratumoral T-cell activation via expression of bifunctional-T-cell ...